Introduction
At present, imaging by PET/CT has established its role in the diagnosis of several diseases, especially in the field of oncology. 
Historical facts
The first available publication dedicated to positron emission tomography (PET) in Poland is the interview with Prof. Wiesław Graban from 1983 [2] .
One of the pioneers of nuclear medicine in our country, he 
Number of PET studies in Poland
In 2011 28 199 PET studies were performed in total: 17 881
(63 %) in public centres and 10 318 (37%) in non-public centres ( Figure   3 ). These data indicate a significant increase (multiplication by a factor of 2.4) in the number of PET studies performed last year in comparison with the total number performed in 2008, which was 11 671 [3] .
Oncology represented 97.5%, neurology -0.7%, cardiology -0.7 %, and other diagnostics -1.0 % of the studies performed in 2011.
Radiopharmaceuticals
The radiopharmaceutical used in most clinical studies (> 92%) is fluorodeoxyglucose labelled with fluorine F-18 (18F-FDG, Table 2 will also be associated with the implementation of PET-MRI [4] .
